Adverse mortality effect of central sympathetic inhibition with sustained‐release moxonidine in patients with heart failure (MOXCON)

  title={Adverse mortality effect of central sympathetic inhibition with sustained‐release moxonidine in patients with heart failure (MOXCON)},
  author={Jay Norman Cohn and Marc A. Pfeffer and Jean L. Rouleau and Norman Sharpe and Karl Swedberg and Matthias Straub and Curtis G. Wiltse and Theressa J. Wright},
  journal={European Journal of Heart Failure},
Case 19: Data Monitoring Experience in the Moxonidine Congestive Heart Failure Trial
The MOXonidine CONgestive Heart Failure Trial was a randomized placebo-controlled trial designed to evaluate reliably the effects of moxonidine, a central sympathetic inhibitor, on mortality and
Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection
Moxonidine is the newest, second-generation, centrally acting antihypertensive agent. It has selective agonist activity at imidazoline I1 receptors and less adverse effects than the other centrally
Neurohormonal Blockade in Heart Failure.
An assessment of the major neurohormonal systems and their therapeutic blockade in patients with chronic HF with reduced left ventricular ejection fraction and in sinus rhythm is provided.
A perspective on sympathetic renal denervation in chronic congestive heart failure
The pathophysiology of HF is reviewed for better understanding of the interplay between the cardiovascular system and the kidney and the available evidence on the role of RDN in HF therapy is presented.
Central sympatholytic drugs for the treatment of hypertension: back to the future?
In this issue of the Journal, Esler et al. [1] present a remarkable study on the neurohumoral effects of the sympatholytic agent rilmenidine in hypertensive patients. The authors have treated
Pharmacologic modulation of parasympathetic activity in heart failure
The current status of the published literature on pharmacologic influences on the parasympathetic nervous system by both conventional and experimental drugs targeting heart failure as well as drugs that more directly influence vagal tone are discussed.
Central Sympathetic Inhibition to Reduce Postablation Atrial Fibrillation Recurrences in Hypertensive Patients: A Randomized, Controlled Study
Treatment with moxonidine is associated with less AF recurrences after ablation treatment for drug-refractory AF in patients with hypertension, and the observed effect does not appear to depend on the antihypertensive action of this agent.


Effects of Sustained-Release Moxonidine, an Imidazoline Agonist, on Plasma Norepinephrine in Patients With Chronic Heart Failure
Plasma norepinephrine was markedly reduced in a dose-related manner by moxonidine SR, accompanied by evidence of reverse remodeling, but also by an increase in adverse events.
Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.
The data suggest that the addition of hydralazine and isosorbide dinitrate to the therapeutic regimen of digoxin and diuretics in patients with chronic congestive heart failure can have a favorable effect on left ventricular function and mortality.
Effect of carvedilol on survival in severe chronic heart failure.
Suppressing sympathetic activation in congestive heart failure. A new therapeutic strategy.
Sympathetic suppression with clonidine in congestive heart failure reduces preload, heart rate, and arterial pressure, all indexes of myocardial energy demand; the lack of significant reduction in systemic vascular resistance and increase in cardiac output might be attributable in part to enhanced release of vasopressin.
Acute and Short-Term Effects of Clonidine in Heart Failure
Resting of the heart by decreasing heart rate, systemic arterial blood pressure, and venous tone are thought by the authors to be major contributing factors to the observed beneficial effect of chronic oral clonidine in chronic heart failure.